Articles tagged "Kidney/liver transplantation"

2021 American Transplant Congress
SARS-CoV-2 Infection in Solid Organ Transplant Recipients: A Retrospective Cohort Study
A. Adeel
Infectious Diseases, University of Massachusetts, Worcester, MA
*Purpose: Initial studies of COVID-19 in solid organ transplant (SOT) recipients demonstrated high mortality rates, but more recent comparative data shows contradictory results.*Methods: We evaluated…
2021 American Transplant Congress
Covid-19 in Hiv-infected Solid Organ Transplant Recipients: A Case Series
M. Ramanathan, A. Fernandez, Y. Natori, J. Simkins, J. Camargo, M. Morris, N. Rivera, M. Loebe, G. Ciancio, L. Abbo, A. Mattiazzi, G. Guerra, S. Anjan
University of Miami, Miami, FL
*Purpose: Coronavirus disease 2019 (COVID-19) is associated with increased mortality and morbidity in immunosuppressed patients. Data on management and outcomes in HIV-infected solid organ transplant…
2021 American Transplant Congress
Nurse and Nurse Practitioner-lead Monoclonal Antibody Initiative for Solid Organ Transplant (sot) Recipients with Covid-19
W. Cochran¹, R. Avery², D. Brennan², N. Lawrence², A. Brown², S. Sullivan², B. Adams², M. McCarthy², S. Ellis², F. Naqvi², E. Kraus², N. Alachkar², S. Alasfar², F. Al Ammary², J. Horn², L. Hartman², L. Fessler², S. Purekal², Z. Siddiqui², D. Carter², J. Ficke², M. Kantsiper², L. Boyer², I. Gupta², A. Gurakar², D. Ostrander², J. Langlee², S. Shoham², K. Marr², P. Shah²
¹Johns Hopkins Comprehensive Transplant Center, Baltimore, MD, ²Johns Hopkins, Baltimore, MD
*Purpose: Monoclonal antibody (mAB) infusion (bamlanivimab or casirivimab/imdevimab) for symptomatic, non-hypoxemic, high-risk outpatients with COVID-19 infection, is an available early intervention for COVID-19+ SOT recipients.…
2021 American Transplant Congress
Post-Transplant Lymphoproliferative Disorder as a Trigger for Hemophagocytic Lymphohistiocytosis in Solid Organ Transplant – Case Series
M. Doraiswamy, P. Singh, T. Pesavento
Comprehensive Transplant Center, The Ohio State University Wexner Medical Center, Columbus, OH
*Purpose: Hemophagocytic Lymphohistiocytosis (HLH) is a hyperinflammatory syndrome characterized by cytokine storm from the activated reticuloendothelial system. Due to the nonspecific presentation and overlap with…
2021 American Transplant Congress
Efficacy of Hope: Analysis of Quality HIV+ Deceased Donor Organ Availability
G. E. Owens¹, B. Shelton¹, P. MacLennan¹, D. Sawinski², J. E. Locke¹
¹Transplant, University of Alabama at Birmingham, Birmingham, AL, ²Transplant, University of Pennsylvania, Philadeplphia, PA
*Purpose: The purpose of this study is to understand the number of organs actually available for HIV+ to HIV+ transplant utilizing data on a national…
2021 American Transplant Congress
Status of Kidney Allocation in Liver-kidney Transplants Before and After the UNOS/OPTN Policy
J. Oveyssi, M. Hussain, P. Homkrailas, S. Bunnapradist
Department of Internal Medicine: Division of Transplant Nephrology, UCLA, Los Angeles, CA
*Purpose: On August 10, 2017 the United Network for Organ Sharing (UNOS) enacted policies 9.7 and 8.5G to establish medical criteria for simultaneous liver-kidney (SLK)…
2021 American Transplant Congress
Single Incision Simultaneous Liver Kidney Transplantation: Outcomes and Feasibility
D. Imai, Y. Sambommatsu, A. Khan, S. Lee, A. Sharma, V. Kumaran, D. Bruno, A. Cotterell, C. Bhati, M. F. Levy
Virginia Commonwealth University, Richmond, VA
*Purpose: Simultaneous liver and kidney transplantation (SLK) is indicated in patients with concomitant end stage liver disease and severe chronic kidney disease or end stage…
2021 American Transplant Congress
Rabbit Anti-thymocyte Globulin Induction is Not Associated with Improved Outcomes in Liver Transplant Recipients
P. Nguyen, N. Wilson, G. Saracino, R. Patel, S. K. Asrani, G. Testa, T. Sam
Baylor University Medical Center, Dallas, TX
*Purpose: Controversy remains on the role of rabbit anti-thymocyte globulin (rATG) induction for calcineurin inhibitor (CNI) delay after liver transplantation (LT). We examined the effect…
2021 American Transplant Congress
Clazakizumab for the Treatment of Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients: Phase 3 IMAGINE Study Design
P. Nickerson¹, G. Böhmig², S. Chadban³, D. Kumar⁴, R. B. Mannon⁵, T. van Gelder⁶, S. Adler⁷, E. Chong⁷, A. Djamali⁸
¹University of Manitoba, Winnipeg, MB, Canada, ²Medical University of Vienna, Vienna, Austria, ³University of Sydney, Sydney, Australia, ⁴University of Toronto, Toronto, ON, Canada, ⁵University of Nebraska Medical Center, Omaha, NE, ⁶Leiden University Medical Center, Leiden, Netherlands, ⁷CSL Behring, King of Prussia, PA, ⁸University of Wisconsin, Madison, WI
*Purpose: Chronic active antibody-mediated rejection (CAMR) is a major cause of allograft loss with no approved drugs for its treatment. Currently, off-label regimens recommended by…
2021 American Transplant Congress
Machine Perfusion of Kidney Grafts in Simultaneous Liver Kidney Transplantation: National Trends and Outcomes
A. Chang¹, M. Chen¹, P. Abt¹, T. Bittermann²
¹Surgery, University of Pennsylvania, Philadelphia, PA, ²Gastroenterology, University of Pennsylvania, Philadelphia, PA
*Purpose: In this study we analyze the SRTR liver data set to determine the trends in machine perfusion of kidney grafts prior to SLK and…

« Previous Page
1
…
3
4
5
6
7
…
24
Next Page »